Upstate Active Clinical Trials
Study Title:A MULTICENTER, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND,
PARALLEL-GROUP CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IMMUNE
GLOBULIN INTRAVENOUS (HUMAN) FLEBOGAMMA® 5% DIF IN PATIENTS WITH POST-POLIO
What is the purpose of the study?The purpose of this research is to test how well a human immunoglobulin concentrate named Flebogamma® 5% DIF (hereafter referred to as Flebogamma) improves your PPS symptoms such as walking capacity, pain, overall quality of life, fatigue and muscle strength. Flebogamma is the investigational drug. Investigational means that is has not been approved by any health authority (government authorities) such as the US Food and Drug Administration (FDA) and is still being tested for safety and effectiveness.
Upstate Institutional Review Board (IRB) Number:700301
Study Phase:Phase II
Patient Age Group:Adults
Principal Investigator:Jenny A Meyer
What is involved if I participate?
- How long is the study?
Approx. 18 Months.
Who can I contact for more information?
Name: Marielle N De masi